drugset / Trial / NCT01968915

Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors

NCT01968915

Phase 1 Completed 9 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate safety and tolerability to estimate the maximum tolerated dose and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors.

Timeline

Start
2013-11
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LCL161 Small molecule Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications